CoChat

Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials

Open access
Rothwell, Peter M, Cook, Nancy R, Gaziano, J Michael, Price, Jacqueline F, Belch, Jill F F, Roncaglioni, Maria Carla, Morimoto, Takeshi, Mehta, Ziyah · 2018 · The Lancet

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Background A one-dose-fits-all approach to use of aspirin has yielded only modest benefits in long-term prevention of cardiovascular events, possibly due to underdosing in patients of large body size and excess dosing in patients of small body size, which might also affect other outcomes. Methods Using individual patient data, we analysed the modifying effects of bodyweight (10 kg bands) and height (10 cm bands) on the effects of low doses (≤100 mg) and higher doses (300–325 mg or ≥500 mg) of aspirin in randomised trials of aspirin in primary prevention of cardiovascular events. We stratified the findings by age, sex, and vascular risk factors, and validated them in trials of aspirin in secondary prevention of stroke. Additionally, we assessed whether any weight or height dependence was evident for the effect of aspirin on 20-year risk of colorectal cancer or any in-trial cancer. Results Among ten eligible trials of aspirin in primary prevention (including 117 279 participants), bodyweight varied four-fold and trial median weight ranged from 60·0 kg to 81·2 kg (p<0·0001). The ability of 75–100 mg aspirin to reduce cardiovascular events decreased with increasing weight (p interaction =0·0072), with benefit seen in people weighing 50–69 kg (hazard ratio [HR] 0·75 [95% CI 0·65–0·85]) but not in those weighing 70 kg or more (0·95 [0·86–1·04]; 1·09 [0·93–1·29] for vascular death). Furthermore, the case fatality of a first cardiovascular event was increased by low-dose aspirin in people weighing 70 kg or more (odds ratio 1·33 [95% CI 1·08–1·64], p=0·0082). Higher doses of aspirin (≥325 mg) had the opposite interaction with bodyweight (difference p interaction =0·0013), reducing cardiovascular events only at higher weight (p interaction =0·017). Findings were similar in men and women, in people with diabetes, in trials of aspirin in secondary prevention, and in relation to height (p interaction =0·0025 for cardiovascular events). Aspirin-mediated reductions in long-term risk of colorectal cancer were also weight dependent (p interaction =0·038). Stratification by body size also revealed harms due to excess dosing: risk of sudden death was increased by aspirin in people at low weight for dose (p interaction =0·0018) and risk of all-cause death was increased in people weighing less than 50 kg who were receiving 75–100 mg aspirin (HR 1·52 [95% CI 1·04–2·21], p=0·031). In participants aged 70 years or older, the 3-year risk of cancer was also increased by aspirin (1·20 [1·03–1·47], p=0·02), particularly in those weighing less than 70 kg (1·31 [1·07–1·61], p=0·009) and consequently in women (1·44 [1·11–1·87], p=0·0069). Interpretation Low doses of aspirin (75–100 mg) were only effective in preventing vascular events in patients weighing less than 70 kg, and had no benefit in the 80% of men and nearly 50% of all women weighing 70 kg or more. By contrast, higher doses of aspirin were only effective in patients weighing 70 kg or more. Given that aspirin's effects on other outcomes, including cancer, also showed interactions with body size, a one-dose-fits-all approach to aspirin is unlikely to be optimal, and a more tailored strategy is required. Funding Wellcome Trust and National Institute for Health Research Oxford Biomedical Research Centre.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31133-4

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effect of low-dose aspirin versus control on risks of cardiovascular events, death, and major bleeding according to bodyweight in trials of aspirin in primary prevention The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. BMI=body-mass index. HR=hazard ratio.
Figure 1 Effect of low-dose aspirin versus control on risks of cardiovascular events, death, and major bleeding according to bodyweight in trials of aspirin in primary prevention The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. BMI=body-mass index. HR=hazard ratio.CC BY · PubMed Central
Figure 2 Effect of low-dose aspirin versus control on risk of all cardiovascular events and of all cardiovascular events and death in women, stratified by bodyweight The analysis of the six trials of aspirin in primary prevention is shown for all participants (top) and with exclusion of participants who were assigned to vitamin E (middle). The bottom two panels are for aspirin in secondary prevention in the ESPS-2 trial.28 The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. HR=hazard ratio.
Figure 2 Effect of low-dose aspirin versus control on risk of all cardiovascular events and of all cardiovascular events and death in women, stratified by bodyweight The analysis of the six trials of aspirin in primary prevention is shown for all participants (top) and with exclusion of participants who were assigned to vitamin E (middle). The bottom two panels are for aspirin in secondary prevention in the ESPS-2 trial.28 The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. HR=hazard ratio.CC BY · PubMed Central
Figure 3 Effect of higher-dose aspirin versus control, stratified by bodyweight and dose of aspirin The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. The analysis included all participants in trials of higher-dose aspirin versus control in primary or secondary prevention of cardiovascular events and cardiovascular events or death (analyses confined to trials in primary prevention are in appendix pp 16, 17). HR=hazard ratio.
Figure 3 Effect of higher-dose aspirin versus control, stratified by bodyweight and dose of aspirin The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. The analysis included all participants in trials of higher-dose aspirin versus control in primary or secondary prevention of cardiovascular events and cardiovascular events or death (analyses confined to trials in primary prevention are in appendix pp 16, 17). HR=hazard ratio.CC BY · PubMed Central
Figure 4 Effect of aspirin versus control on risk of cardiovascular events in trials in primary prevention, stratified by bodyweight, height, and dose The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. The analysis was limited to participants who were not obese (body-mass index <30 kg/m2). HR=hazard ratio.
Figure 4 Effect of aspirin versus control on risk of cardiovascular events in trials in primary prevention, stratified by bodyweight, height, and dose The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. The analysis was limited to participants who were not obese (body-mass index <30 kg/m2). HR=hazard ratio.CC BY · PubMed Central
Figure 5 Effect of aspirin versus control on 20-year risk of colorectal cancer, stratified by aspirin dose and age The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. The analysis included the five trials15, 16, 17, 18, 19 with post-trial follow-up data and data on bodyweight. (A) Included participants treated with any dose and of any age. (B) Included participants treated with any dose who were younger than 70 years. (C) Included participants treated with 75–100 mg aspirin who were younger than 70 years. (D) Included participants treated with ≥325 mg aspirin who were younger than 70 years. HR=hazard ratio.
Figure 5 Effect of aspirin versus control on 20-year risk of colorectal cancer, stratified by aspirin dose and age The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. The analysis included the five trials15, 16, 17, 18, 19 with post-trial follow-up data and data on bodyweight. (A) Included participants treated with any dose and of any age. (B) Included participants treated with any dose who were younger than 70 years. (C) Included participants treated with 75–100 mg aspirin who were younger than 70 years. (D) Included participants treated with ≥325 mg aspirin who were younger than 70 years. HR=hazard ratio.CC BY · PubMed Central
Figure 6 Effect of aspirin (all doses) versus control on early cancer risk in trials of aspirin in primary prevention of vascular events The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. (A) 3-year risk of cancer stratified by age. (B) 5-year risk of death due to cancer stratified by age. (C) Cancer risk stratified by year of follow-up in participants aged ≥70 years who had low weight for dose received (<70 kg for 75–100 mg and <80 kg for ≥325 mg). (D) Cancer risk stratified by year of follow-up in participants aged ≥70 years who had low height for dose received (1·6 m for 75–100 mg and <1·8 m for ≥325 mg). HR=hazard ratio.
Figure 6 Effect of aspirin (all doses) versus control on early cancer risk in trials of aspirin in primary prevention of vascular events The size of the circles representing the point estimates of the HRs is proportional to the inverse of the variance of the estimate. (A) 3-year risk of cancer stratified by age. (B) 5-year risk of death due to cancer stratified by age. (C) Cancer risk stratified by year of follow-up in participants aged ≥70 years who had low weight for dose received (<70 kg for 75–100 mg and <80 kg for ≥325 mg). (D) Cancer risk stratified by year of follow-up in participants aged ≥70 years who had low height for dose received (1·6 m for 75–100 mg and <1·8 m for ≥325 mg). HR=hazard ratio.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. 1997, Efficacy and safety data, J Neurol Sci, 151, S1

Cited by

See all 353

Metadata

Authors
Rothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z.
Affiliations
  • University of Oxford (GB)
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
  • University of Edinburgh (GB)
  • Mario Negri Institute for Pharmacological Research (IT)
  • Hyogo Medical University (JP)
Corresponding author
Rothwell, Peter M
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-08
Volume
392
Issue
10145
Pages
387-399
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2884727639
Cited by
353
References
49
Citations by year
2026: 12 · 2025: 22 · 2024: 29 · 2023: 32 · 2022: 46 · 2021: 51 · 2020: 57 · 2019: 68 · 2018: 36
FWCI
40.10
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
Funders
  • Wellcome Trust
  • National Institute for Health and Care Research
  • Japan Society for the Promotion of Science (18H03032)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
aspirin, body weight, aspirin dose, cardiovascular events, cancer risk, colorectal cancer, vascular death, case fatality, primary prevention, secondary stroke prevention, dose-response interaction, individual patient data, height, individualized dosing, vascular risk factors, diabetes mellitus, sex differences, cardiovascular mortality, cancer mortality, myocardial infarction
MeSH terms
Age Factors, Aged, Aspirin, Body Height, Body Weight, Cardiovascular Diseases, Death, Sudden, Female, Humans, Male, Platelet Aggregation Inhibitors, Risk Factors, Sex Factors, Colorectal Neoplasms, Proportional Hazards Models, Randomized Controlled Trials as Topic, Stroke, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31133-4
The paper
Rothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z. (2018). Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(18)31133-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.